A carregar...
A Phase I Study to Determine the Maximum Tolerated Dose and Safety of Oral LR-103 (1α,24(S)Dihydroxyvitamin D(2)) in Patients with Advanced Cancer
BACKGROUND: The objective of this study was to determine the maximum tolerated dose (MTD) and safety of LR-103, a Vitamin D analogue, in patients with advanced cancer. METHODS: In Step A, patients received once daily oral LR-103 in 14-day cycles with intra-patient dose escalation per accelerated dos...
Na minha lista:
| Publicado no: | J Oncol Pharm Pract |
|---|---|
| Main Authors: | , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2014
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4281509/ https://ncbi.nlm.nih.gov/pubmed/24986793 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1078155214541572 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|